ArriVent director granted 13,562 stock options

ArriVent BioPharma director Chris Nolet received a grant of non-qualified stock options covering 13,562 shares of common stock.

Rhea-AI Filing Summary

ArriVent BioPharma director Chris Nolet received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036. The underlying shares vest on the first anniversary of the June 18, 2026 grant date, conditioned on continued service.

Insider Trade Summary

Grant/Award: 13,562 shares

Grant/Award 1 txn

Insider Nolet Chris

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	13,562	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 13,562 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option grant size: 13,562 options Exercise price: $31.74 per share Expiration date: June 17, 2036 +2 more

5 metrics

Option grant size 13,562 options Non-qualified stock option grant to director Chris Nolet

Exercise price $31.74 per share Strike price for the 13,562 options

Expiration date June 17, 2036 Option term end for the grant

Shares underlying options 13,562 shares Common stock underlying the non-qualified stock options

Holdings after transaction 13,562 derivative securities Total options held from this grant after the award

Key Terms

Non-Qualified Stock Option, exercise price, grant, award, or other acquisition, vesting, +1 more

5 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"conversion_or_exercise_price: 31.7400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"shares underlying this option vest on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-17T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ArriVent BioPharma (AVBP) report for Chris Nolet?

ArriVent BioPharma reported that director Chris Nolet received a grant of 13,562 non-qualified stock options. These options relate to common stock and were awarded as a compensation-related acquisition, not an open-market purchase or sale of existing shares.

How many ArriVent BioPharma (AVBP) options were granted to Chris Nolet?

Chris Nolet was granted non-qualified stock options for 13,562 shares of ArriVent BioPharma common stock. Following this award, his reported derivative holdings from this grant total 13,562 options, reflecting a single new equity-based compensation grant in this filing.

What is the exercise price of Chris Nolet’s ArriVent BioPharma (AVBP) stock options?

The options granted to Chris Nolet carry an exercise price of $31.74 per share. This means he can buy ArriVent BioPharma common stock at $31.74, subject to the options vesting and remaining outstanding through the applicable exercise period.

When do Chris Nolet’s ArriVent BioPharma (AVBP) options vest?

The shares underlying Chris Nolet’s option grant vest on the first anniversary of the June 18, 2026 grant date. Vesting is conditioned on his continued service with ArriVent BioPharma through that one-year vesting date, as specified in the filing’s footnote.

When do Chris Nolet’s ArriVent BioPharma (AVBP) options expire?

Chris Nolet’s non-qualified stock options are scheduled to expire on June 17, 2036. After that expiration date, any unexercised portion of the 13,562 options would lapse, and he would no longer have the right to purchase shares under this grant.

Did ArriVent BioPharma (AVBP) report any open-market buys or sells by Chris Nolet?

The filing reports only a grant of non-qualified stock options to Chris Nolet and no open-market purchases or sales. The transaction code is “A,” indicating a grant or award acquisition rather than a market trade in ArriVent BioPharma common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 09:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nolet Chris

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD SUITE 100

(Street)

NEWTOWN SQUARE PENNSYLVANIA 19073

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$31.74	06/18/2026		A		13,562		06/18/2027(1)	06/17/2036	Common Stock	13,562	$0.00	13,562	D

Explanation of Responses:

1. The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

	By: /s/ James Kastenmayer, Attorney-in-Fact for: Chris Nolet	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)